BioSpace News Archive

Shimadzu Medical Systems USA, completes the integration of Core Medical Imaging Inc., a subsidiary of SMS into the company.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide progress against the company’s 2020 goals

Seneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need, announced today the appointment of Matthew W. Kalnik, Ph.D. as President and Chief Operating Officer (COO) and Dane R. Saglio as Chief Financial Officer (CFO).

Allogene Therapeutics, Inc. today announced that management plans to participate in two upcoming virtual investor conferences. Goldman Sachs Cell Therapy Day Monday, April 6, 2020 9:30 AM PT/12:30 PM ET Canaccord Genuity Horizons in Oncology Conference Wednesday, April 8, 2020 9:45 AM PT/12:45

NOCD, a telehealth company that specializes in identifying and treating people with obsessive-compulsive disorder (OCD), today reported that therapy sessions on its platform have more than doubled since the start of the COVID-19 outbreak in early March.

Healthcare Integrated Technologies, Inc. (“HITC”) is pleased to update our shareholders with a brief overview of the key initiatives we have successfully completed over the past two years.

Complete first quarter 2020 financial results will be announced on Tuesday, April 28, 2020.

Bioasis Technologies Inc. announced that it intends to satisfy its obligation to pay $28,076.55 in interest to the holders of its 15% unsecured debentures issued November 8, 2019 as of March 31, 2020 by issuing 155,980 common shares of the Company.

The German government is readying a massive cash injection to help innovative young companies ride out economic difficulties.

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced the pricing of a public offering for the issuance of an aggregate of 4,166,668 units, each consisting of (i) one pre-funded warrant t